60 DEGREES PHARMACEUTICALS, INC.

SXTP Nasdaq CIK: 0001946563

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 1025 CONNECTICUT AVENUE NW, WASHINGTON, DC, 20036
Mailing Address 1025 CONNECTICUT AVENUE NW, WASHINGTON, DC, 20036
Phone 202-327-5422
Fiscal Year End 1231
EIN 452406880

Financial Overview

FY2025

-$7.37M
Net Income
$5.76M
Total Assets
$-11.73
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 30, 2026 View on SEC
8-K Current report of material events March 20, 2026 View on SEC
8-K Current report of material events March 13, 2026 View on SEC
424B5 Prospectus supplement March 13, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
424B5 Prospectus supplement March 11, 2026 View on SEC
424B5 Prospectus supplement March 2, 2026 View on SEC
8-K Current report of material events February 12, 2026 View on SEC
8-K Current report of material events January 23, 2026 View on SEC
8-K Current report of material events January 21, 2026 View on SEC

Annual Reports

10-K March 30, 2026
  • FDA-approved malaria prevention drug Arakoda provides a core revenue stream.
  • Active expansion efforts into treatments for babesiosis, influenza, and COVID-19.
View Analysis

Material Events

8-K Legal Issue February 12, 2026
High Impact
  • Nasdaq listing secured, successfully resolving the minimum bid price non-compliance.
  • Continued market access, visibility, and liquidity for the company's stock are maintained.
View Analysis

Insider Trading

BUY 1 insiders 3 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.